(NYSEMKT: AIM) Aim Immunotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.59%.
Aim Immunotech's earnings in 2025 is -$16,166,000.On average, 3 Wall Street analysts forecast AIM's earnings for 2025 to be -$18,630,627, with the lowest AIM earnings forecast at -$18,130,332, and the highest AIM earnings forecast at -$19,311,591. On average, 3 Wall Street analysts forecast AIM's earnings for 2026 to be -$9,246,919, with the lowest AIM earnings forecast at -$11,945,314, and the highest AIM earnings forecast at -$6,427,717.
In 2027, AIM is forecast to generate -$4,404,598 in earnings, with the lowest earnings forecast at -$4,273,768 and the highest earnings forecast at -$4,579,037.